

Anzahl Stimmen/Number of Shares





Cytos Biotechnology AG Aktienregister c/o Nimbus AG Ziegelbrückstrasse 82 8866 Ziegelbrücke Schweiz

Reply form for the Extraordinary Shareholders' Meeting of Cytos Biotechnology Ltd on 6 January 2016

Personal attendance
I will attend personally at the Extraordinary Shareholders' Meeting and hereby order an admission card. The admission card will be mailed from 30 December 2015 onwards.
Forms returned in blank will be considered as an application for personal participation. Eligible are the shareholders registered in the share register with voting right as of 29 December 2015.
Authorization
I hereby authorize the proxy voting to: the independent voting rights representative , Mr. Andreas G. Keller, attorney-at-law, Keller Law Office, Postfach 2924, 8021 Zurich, Switzerland, or in his absence by a representative appointed by him, according to the instructions on the back.
any third person.
In this case I will receive the admission card personally. I will send this form directly to the delegate after I filled in the power of proxy on the back.
Electronic registration, proxy voting and instructions to the independent voting rights representative
You have the possibility to order an admission card or to cast a proxy voting to the independent voting rights representative electronically (online). You can register yourself under https://cytos.shapp.ch
Login: Password:
The registration as well as any changes to votes cast to the independent voting rights representative is possible until 4 January 2016.
Date: Signature(s):

The granting of a proxy requires a valid signature. Corporates require collective signatures.

Please return this form in the enclosed reply envelope.

Instructions to the independent voting rights representative

Without explicit written instructions to the contrary, the independent voting rights representative will vote according to the proposals of the Board of Directors.

Pro	oposals (according to the invitation):	Yes	No	Abst.
l.	Ordinary Capital Increase for the Combination with Kuros Biosurgery Holding AG			
2.	Amendments to Authorized and Conditional Capital			
	2.a Reduction of Nominal Value of Conditional Capital			
	2.b Reduction of Nominal Value and Increase of Authorized			
	Capital Control of the Control of th			
	2.c Conditional Share Capital for Employee Benefit Plans			
3.	Compensation of Losses with Capital Contribution Reserve			
4.	Name Change			
5.	Election of new Members of the Board of Directors			
	5.a Election of Didier Cowling			
	5.b Election of Dominik Ellenrieder			
	5.c Election of Arnd Kaltofen-Ehmann			
	5.d Election of Jörg Neermann			
	5.e Election of Vincent Ossipow			
	5.f Election of Gerhard Ries			
	5.g Election of Harry Welten			
6.	Election of the Members of the Compensation Committee			
	6.a Election of Dominik Ellenrieder			
	6.b Election of Arnd Kaltofen-Ehmann			
7.	Compensation for the Members of the Board of Directors and the Executive Committee			
	7.a Vote on Total Non-Performance-Related Compensation for Members of the Board of Directors for the period up to the next ordinary general meetin	g		
	7.b Vote on Options for Members of the Board of Directors for the period up to the next ordinary general meeting			
	7.c Vote on Total Non-Performance-Related Compensation for new Members of the Executive Committee up to 30 June 2016			
	7.d Vote on Total Variable Compensation for new Members of the Executive Committee for the calendar year 2016			
	7.e Vote on Options for Members of the Executive Committee for the calendar year 2016			
8.	Loans and Credits to Members of the Board of Directors and the Executive Committee			